Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Angiotensin Receptor Blockers Clear all

Completed Phase 3 Interventional Results available

Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension

NCT00527514

View directory record Official record

Conditions: Hypertension
Interventions: Amlodipine, Olmesartan medoxomil plus amlodipine; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older

Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 18
States / cities: Buena Park, California • Long Beach, California • Los Angeles, California + 15 more

Source: ClinicalTrials.gov public record

Updated Nov 10, 2009 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome

NCT00429364

View directory record Official record

Conditions: Marfan Syndrome
Interventions: Losartan Potassium, Atenolol; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 6 Months to 25 Years

Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 24
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 18 more

Source: ClinicalTrials.gov public record

Updated Mar 6, 2025 · Synced May 21, 2026, 7:59 PM EDT

Terminated Phase 4 Interventional Results available

Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

NCT02788656

View directory record Official record

Conditions: Congestive Heart Failure
Interventions: Implantable Hemodynamic Monitor, Angiotensin-Converting Enzyme Inhibitor, Angiotensin II Type 1 Receptor Blocker, sacubitril/valsartan; Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older

Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Feb 16, 2020 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 4 Interventional Results available

Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection

NCT04340557

View directory record Official record

Conditions: SARS-CoV Infection
Interventions: Losartan; Drug
Lead sponsor: Sharp HealthCare; Other
Eligibility: 18 Years and older

Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: La Mesa, California • San Diego, California

Source: ClinicalTrials.gov public record

Updated May 25, 2021 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 4 Interventional Results available

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

NCT00153101

View directory record Official record

Conditions: Cardiovascular Diseases
Interventions: Telmisartan, Combination of Telmisartan and Ramipril, Ramipril; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 55 Years and older

Enrollment: 31,546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 100
States / cities: Athens, Alabama • Birmingham, Alabama • Phoenix, Arizona + 84 more

Source: ClinicalTrials.gov public record

Updated May 19, 2014 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 4 Interventional

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

NCT00185120

View directory record Official record

Conditions: Hypertension
Interventions: Olmesartan medoxomil, Hydroclorothiazide, Benazepril, Amlodipine; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older

Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 20
States / cities: Mobile, Alabama • Long Beach, California • Los Angeles, California + 17 more

Source: ClinicalTrials.gov public record

Updated Jan 17, 2012 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 4 Interventional Results available

The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy

NCT00666536

View directory record Official record

Conditions: Hypertension
Interventions: valsartan and amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older

Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Metairie, Louisiana

Source: ClinicalTrials.gov public record

Updated Oct 26, 2016 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

NCT01487109

View directory record Official record

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions: CTP-499, Placebo; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 49
States / cities: Tempe, Arizona • Harrisburg, Arkansas • Little Rock, Arkansas + 38 more

Source: ClinicalTrials.gov public record

Updated Aug 15, 2021 · Synced May 21, 2026, 7:59 PM EDT

Recruiting Phase 3 Interventional

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283

View directory record Official record

Conditions: Chronic Kidney Disease, Proteinuria, Children
Interventions: Finerenone (Kerendia, BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: 1 Year to 18 Years

Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 18
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more

Source: ClinicalTrials.gov public record

Updated May 10, 2026 · Synced May 21, 2026, 7:59 PM EDT

Terminated Phase 4 Interventional Results available

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

NCT03738878

View directory record Official record

Conditions: Hypertension
Interventions: Valsartan, LCZ696, Bradykinin, Substance P, BNP, Sitagliptin; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years

Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Source: ClinicalTrials.gov public record

Updated Aug 2, 2025 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Accepts healthy volunteers

The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function

NCT00001628

View directory record Official record

Conditions: Atherosclerosis, Heart Failure, Congestive, Hypertension, Myocardial Infarction
Interventions: Angiotensin II type 1 receptor antagonists; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed

Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Mar 3, 2008 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 4 Interventional Results available

Efficacy of Losartan in Preventing Progression of COPD

NCT00720226

View directory record Official record

Conditions: COPD, Emphysema, Chronic Bronchitis, Smoking
Interventions: Losartan, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years and older

Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Apr 24, 2017 · Synced May 21, 2026, 7:59 PM EDT

Recruiting Phase 3 Interventional

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035

View directory record Official record

Conditions: Chronic Kidney Disease, Proteinuria
Interventions: Finerenone (Kerendia, BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 17 Years

Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 19
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Source: ClinicalTrials.gov public record

Updated Apr 16, 2026 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 4 Interventional Results available

Angiotensin II in General Anesthesia

NCT03733145

View directory record Official record

Conditions: Hypertension
Interventions: Angiotensin II; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years and older

Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Source: ClinicalTrials.gov public record

Updated Aug 23, 2025 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 4 Interventional

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

NCT04113109

View directory record Official record

Conditions: Heart Failure
Interventions: LCZ 696, Icatibant, placebo, Para-aminohippurate, Iohexol; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older

Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Source: ClinicalTrials.gov public record

Updated Aug 23, 2025 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 4 Interventional

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

NCT04649229

View directory record Official record

Conditions: Heart Failure
Interventions: LCZ 696, Placebo, Para-aminohippurate, Iohexol, Aprepitant; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older

Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Source: ClinicalTrials.gov public record

Updated Mar 16, 2026 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 4 Interventional Results available

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

NCT00403481

View directory record Official record

Conditions: Hypertension
Interventions: olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older

Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 27
States / cities: Birmingham, Alabama • Mesa, Arizona • Searcy, Arkansas + 24 more

Source: ClinicalTrials.gov public record

Updated Nov 2, 2016 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional Results available

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

NCT02678000

View directory record Official record

Conditions: Chronic Kidney Disease (CKD)
Interventions: LHW090, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years

Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Anaheim, California • Lakewood, Colorado • Miami Lakes, Florida + 4 more

Source: ClinicalTrials.gov public record

Updated Oct 5, 2021 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional

The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function

NCT00001629

View directory record Official record

Conditions: Atherosclerosis, Heart Failure, Congestive, Hypertension, Myocardial Infarction
Interventions: Angiotensin II type 1 receptor antagonists; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed

Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Mar 3, 2008 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 4 Interventional

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

NCT00185068

View directory record Official record

Conditions: Hypertension
Interventions: Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Hydrochlorothiazide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older

Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 16
States / cities: Fort Lauderdale, California • Long Beach, California • Roseville, California + 13 more

Source: ClinicalTrials.gov public record

Updated Sep 15, 2005 · Synced May 21, 2026, 7:59 PM EDT

Completed Not applicable Interventional Results available

Cardiomyopathy in DMD: Lisinopril vs. Losartan

NCT01982695

View directory record Official record

Conditions: Duchenne Muscular Dystrophy (DMD), Cardiomyopathy
Interventions: Losartan, Lisinopril; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Male only

Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Davis, California • Kansas City, Kansas • Boston, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated Mar 20, 2017 · Synced May 21, 2026, 7:59 PM EDT

Completed No phase listed Observational

A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients

NCT07376265

View directory record Official record

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 1,249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Source: ClinicalTrials.gov public record

Updated Feb 3, 2026 · Synced May 21, 2026, 7:59 PM EDT

Completed No phase listed Observational

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

NCT05096143

View directory record Official record

Conditions: Heart Failure
Interventions: Sacubitril/valsartan, ACEi/ARB; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 42,269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: East Hanover, New Jersey

Source: ClinicalTrials.gov public record

Updated Dec 20, 2021 · Synced May 21, 2026, 7:59 PM EDT

Completed Not applicable Interventional Results available

Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019

NCT04338009

View directory record Official record

Conditions: COVID-19
Interventions: Discontinuation of ARB/ACEI, Continuation of ARB/ACEI; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older

Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Apr 8, 2021 · Synced May 21, 2026, 7:59 PM EDT